Mogroside III-E

TargetMol
Product Code: TAR-TN1936
Supplier: TargetMol
CodeSizePrice
TAR-TN1936-1mg1mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1936-5mg5mg£226.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1936-10mg10mg£299.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1936-1mL1 mL * 10 mM (in DMSO)£336.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1936-25mg25mg£454.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1936-50mg50mg£622.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1936-100mg100mg£871.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Mogroside III-E is a cucurbitane-type compound isolated from Siraitia grosvenorii, has anti-inflammatory activity, it attenuates LPS-induced acute lung injury in mice partly through regulation of the TLR4/MAPK/NF-κB axis via AMPK activation. It also has anti-fibrotic activity, it reduces pulmonary fibrosis through Toll-Like receptor 4 pathways.
CAS:
88901-37-5
Formula:
C48H82O19
Molecular Weight:
963.165
Pathway:
Apoptosis; Immunology/Inflammation
Purity:
0.9973
SMILES:
[H][C@@]1(CC[C@@]2(C)[C@]3([H])CC=C4[C@@]([H])(CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C4(C)C)[C@]3(C)[C@H](O)C[C@]12C)[C@H](C)CC[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@]1([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)(C)O
Target:
IL Receptor; TNF; TLR

References

Xue W , Mao J , Chen Q , et al. Mogroside IIIE Alleviates High Glucose-Induced Inflammation, Oxidative Stress and Apoptosis of Podocytes by the Activation of AMPK/SIRT1 Signaling Pathway[J]. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13:3821-3830.